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Summary 
Thrombopoietin (TPO) has recently been cloned and shown to regulate megakaryocyte and 
platelet production by activating the cytokine receptor c-mpl. To determine whether TPO is 
the  only ligand for c-mpl and the  major regulator of megakaryocytopoiesis, TPO deficient 
mice were generated by gene targeting. TPO -/- mice have a >80% decrease in their platelets 
and megakaryocytes but have normal levels of all the other hematopoietic cell types. A gene 
dosage effect observed in heterozygous mice suggests  that the TPO gene is constitutively ex- 
pressed and that the circulating TPO level is directly regulated by the platelet mass. Bone mar- 
row from TPO -/- mice have decreased numbers of megakaryocyte-committed progenitors as 
well as lower ploidy in  the megakaryocytes that are present.  These results  demonstrate that 
TPO alone is the major physiological regulator of both proliferation and differentiation ofhe- 
matopoietic progenitor cells into mature megakaryocytes but that TPO is not critical to the fi- 
nal step ofplatelet production. 
p latelets are small anucleated cells produced from mega- 
karyocytes.  Normal  hemostasis  requires  the  mainte- 
nance of an adequate number of circulating platelets in the 
peripheral blood. Multiple cytokines (IL-1, IL-3, IL-6, IL-11, 
GM-CSF,  and  erythropoietin)  stimulate  megakaryocyto- 
poiesis both in vitro and in vivo (1,  2), but their effect is 
only modest compared with the recently identified ligand 
for  the  protooncogene  c-mpl  (3-9).  This  ligand,  called 
thrombopoietin (TPO), is a novel cytokine with a unique 
structure;  the  NH2-terminal  domain  is  homologous  to 
erythropoietin, and the COOH-terminal glycosylated do- 
main is unrelated to any known protein (6-8). In vitro and 
in vivo experiments with recombinant TPO indicate that 
it stimulates  both  megakaryocyte  colony  formation  and 
megakaryocyte maturation  (6,  8-10).  TPO stimulates the 
formation ofCFU-megakaryocytes (CFU-megs) both alone 
and  in  combination  with  early acting  factors  (9,  11).  It 
stimulates the production ofmegakaryocytes and functional 
platelets from enriched murine or human stem cell popula- 
tions (12,  13). Injection of  TPO into mice increases platelet 
counts 4-6-fold and stimulates a 20-fold increase in bone 
marrow megakaryocytes (7,  9).  The importance of c-mpl 
in  the  physiological  regulation  of platelet  production  in 
vivo was demonstrated by the generation of mice deficient 
in c-mpl (14).  These mice exhibit an 85% reduction in pe- 
ripheral  platelet  counts  and  in  marrow  and  spleen  mega- 
karyocytes. Although these results demonstrate that c-mpl 
is critical in thrombopoiesis, they do not exclude the possi- 
bility that another receptor could be activated by TPO and 
could therefore be responsible for the remaining platelets in 
the c-mpl  -/- mice. To investigate this, and the mechanism 
of control  of megakaryocyte and  platelet  production  by 
TPO, we have generated mice deficient in TPO by using 
homologous recombination. 
Materials and Methods 
Embryonic Stem (ES) Cell-Targeted Mutation.  Genomic  clones 
were isolated from a mouse  129 library using the human TPO 
cDNA as a probe (6). The targeting vector was constructed from 
a 10-kb XhoI-SacI subclone. The targeting vector (20 I.Lg) was 
linearized and electroporated at 275 V, 200 I-~F, using a BTX 300 
electroporator  (BTX Inc., San Diego,  CA) into ES.D3 C-12, a 
subclone of D3 ES cells (a gift from T. Doetschman,  University 
of Cincinnati,  Cincinnati,  OH)  (15). Cells were  subjected  to 
G418 selection at 400 p,g/ml for 10 d. Single-colony wells were 
expanded for DNA isolation and Southern blot analysis, using a 
routine  oligo probe 5' to the XhoI site on the targeting vector. 
Five  gene-targeted  clones  were  selected  to  generate  chimeric 
mice by microinjection into the blastocele cavity of  3.5-d C57B1/ 
6J blastocysts (16). Chimeric  males were mated with C57B1/6J 
females, and agouti  color offspring were screened for germline 
transmission by PCtL analysis for the neo' gene and confirmed by 
Southern blot analysis of tail DNA for the mutant  TPO allele. 
Heterozygous mice were interbred to obtain homozygous animals. 
PCR-based Genotyping of TPO-df/ident Mice.  The  presence  of 
the mutated TPO allele was detected using PCR primers to the 
wild-type allele: p.TPO.SacI  (5'-GGTGAATGTAACCTGGGA- 
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site;  and p.TPO.SalI  (5'-GTCGACCCTTTGTCTATCCCT-3'), 
an oligonucleotide in exon 4 upstream of the Sail site. Homolo- 
gous recombination places the 1.9-kb pgk-Neo gene between this 
oligo pair. The reaction conditions favor the smaller 330-bp wild- 
type product such that the predicted 2.1-kb band is not detected. 
An  additional  set  of oligo  primers  5'-CGGTTCTTTTTGTC- 
AAGAC-3'  and  5'-ATCCTCGCCGTCGGGCATGC-3'  spe- 
cific for the neo' gene are used in each reaction to detemine het- 
erozygous mice. Each reaction is performed with 1 Ixg of mouse 
genomic DNA prepared from tail biopsies using a PCR reaction 
kit (Perkin-Elmer, Norwalk, CT). Each reaction was analyzed on 
a 2% agarose TBE gel stained with ethidium bromide. 
Northern Blot Analysis.  Poly(A) +  RNA  was  prepared  from 
the  livers and kidneys of mice  as  described  (17).  2  p~g of liver 
mRNA or 5 ~g of kidney mRNA per lane was resolved on a 1.2% 
agarose-formaldehyde gel and transferred to  a  nylon membrane 
(Genescreen Plus; Du Pont,  Wilmington, DE).  The  membrane 
was  hybridized  overnight  with  a  random-primed  32p-labeled 
cDNA  probe  containing the  entire  coding  region  of murine 
TPO.  The  membrane was  washed  at  42~  in 0.2￿  SSC/0.1% 
SDS  and  exposed  overnight to  a  phosphor  imaging plate  (Fuji, 
Stamford, CT). 
Ploidy Analysis of Megakaryocytes.  A  Percoll step gradient (20, 
40, 60, and 80%)  was used to enrich for megakaryocytes in bone 
marrow. Aproximately 120  ￿  106 bone marrow cells per 13-ml 
gradient were spun at 3,000 g for 30 re.in at 10~  Cells from the 
20/40%  interface were  collected, washed  in HBSS,  and stained 
with anti-CD61 (integrin-]33 chain)-FITC (PharMingen, San Di- 
ego,  CA) and the DNA intercalating fluorescent dye propidium 
iodide. The DNA content in CD61 + cells was quantified by two- 
color flow cytometry (Epics Elite; Coulter Corp., Hialeah, FL). 
CFU-meg Assay.  Megakaryocyte colony formation was assayed 
in semisolid agar culture of bone marrow of 6-10-wk-old mice as 
described (11)  in the presence of 100 ng/ml of the various cyto- 
kines. After 7 d, the plates were dried and stained for acetylcho- 
linesterase (18).  Megakaryocyte colonies were defined as stained 
colonies containing three or more cells. 
Results  and Discussion 
A  targeting vector  containing a  10-kb  TPO  mouse  ge- 
nomic  clone  (Fig,  1  A)  was  electroporated  into  ES  cells. 
The  construct was  designed  to  remove  23  amino acids  of 
the third coding exon via insertion of a  neo  r cassette.  Dele- 
tion of this  fragment located  in the  erythropoietin  (EPO) 
homology  domain that  is responsible for receptor binding 
and activation (6) should ensure that homologous recombi- 
nation will lead to  a  nonfunctional TPO  gene.  Gene tar- 
geting was detected in 1 of 80 ES  colonies screened, and 5 
colonies  were  selected  for  microinjection into  blastocysts 
(Fig.  1  B). All five clones gave germ line transmission, and 
three separate lines were interbred to generate homozygous 
gene-targeted mice  (TPO-/-).  The  litters generated had a 
normal Mendelian distribution of the three  genotypes,  in- 
dicating  viable  fetal  development  of the  TPO -/-  mice. 
The adult mice were healthy and displayed no overt abnor- 
malities. Expression  of TPO  mRNA  in the liver and kid- 
ney was  assessed  by  Northern  blot  analysis  (Fig.  1  C).  A 
1.8-kb  band  can  be  detected  in  both  tissues  in  TPO +/§ 
mice.  The  band  intensity is  reduced  by  half in  the  het- 
erozygotes, as measured by quantification of the radioactiv- 
ity  present  in  each  band  using  a  PhosphoImager  (model 
BAS2000;  Fuji, Stamford,  CT).  TPO  mRNA  is undetect- 
able in the liver and kidney of TPO -/-  animals. 
Figure  1.  Targeting  of the TPO gene by homolo- 
gous recombination.  (/t)  Structure  of the TPO  gene 
(19) and gene-targeting vector. The restriction enzyme 
sites are  those  from  the  mouse,  whereas  the  intron 
exon  organization  is  taken  from  the  human. A  neo  T 
gene under control  of the Pgk promoter (19) was in- 
serted between the Sail site in the third exon of TPO 
and the XhoI site present in the following intron. An 
oligonucleotide probe was designed from sequences 5' 
to those present on the targeting vector. After homolo- 
gous recombination, the mutated allele was detected by 
the addition  of a HindllI site from the neo  r gene.  (B) 
Targeting of the TPO gene in ES cells. (C) Northern 
blot analysis  of TPO expression in c-mpl  -/-, TPO  /-, 
TPO  -/+,  and  wild-type  mice.  RNA  was  prepared 
from the livers and kidney of the indicated mice, sepa- 
rated  on agarose-formaldehyde  gels, transferred to  a 
nylon membrane,  and hybridized with a TPO DNA 
probe, 
652  Megakaryocytopoiesis in Thrombopoietin-deficient Mice Complete  blood cell counts performed on TPO -/-  and 
TPO +/+  mice  revealed  an  88%  drop  in platelet  counts  in 
the  gene-targeted  animals,  with  100%  penetrance  in  mice 
derived from three independent ES cell clones (/9 <0.0001) 
(Fig.  2  A).  There was also a  significant increase in volume 
of the  remaining  platelets,  with  a  mean  of 8.7  cubic  mi- 
crometers for TPO -/-  mice compared with  4.7  cubic mi- 
crometers  for TPO +/+  mice  (p  <0.0001).  These  findings 
are  similar  to  those  observed  in  the  c-mpl  -/-  mice  (14). 
However,  a significant alteration in platelet counts  (67% of 
wild type) was observed in TPO heterozygous mice. These 
data suggest that the  TPO -/-  mice are unable  to produce 
normal  levels  of megakaryocytes,  and  therefore  platelets, 
because of the loss of a functional TPO gene, and that even 
the  loss  of one  allele  affects platelet  levels.  We  previously 
detected an increased level of TPO  activity in the serum of 
c-mpl -/-  mice  that  was  comparable  to  levels  present  in 
aplastic porcine plasma  (14).  No  increase in  IL-3,  IL-6, or 
GM-CSF,  which  are  other  cytokines  with  a  weak  mega- 
karyocytopoietic ability, could be detected by ELISA-based 
assays.  These  data  suggest  that  in  response  to  throm- 
bocytopenia,  TPO  levels  are  upregulated.  However,  the 
gene  dosage  effect  in  TPO +/-  mice  would  argue  against 
mechanisms  involving  regulation  of  TPO  production. 
Northern blot analysis of TPO -/-, TPO +/-, and wild-type 
mice confirms that there  is no  regulation  of TPO  mRNA 
expression,  as the  heterozygous mice had reduced  mRNA 
levels.  It was unexpected  that the regulator ofplatelet pro- 
duction,  which  shares  many  similarities  with  erythropoi- 
etin,  appears to be constitutively expressed and is not regu- 
lated  at  the  transcriptional  level  in  response  to  a  platelet 
sensing  mechanism.  This  system would  have  been  similar 
to  the  sensing  mechanism  by  which  the  kidney  controls 
erythrocyte production  through  transcription  of the eryth- 
ropoietin  gene  (20).  Instead,  our  results  support  the  con- 
cept  of circulating  levels  of TPO  being  directly  regulated 
by platelet mass (21). When platelet levels are normal,  they 
will bind and remove from the circulation TPO released by 
the  liver  and/or  the  kidney,  In  thrombocytopenic  situa- 
tions,  the  circulating  concentration  of TPO  will  therefore 
increase and stimulate platelet production  by bone marrow 
megakaryocytes.  This  regulatory  mechanism  whereby  the 
ligand availability is controlled  by the mature cell could be 
similar to the way the G-CSF level is regulated  in neutro- 
penic situations  (22).  A  gene dosage  effect is also observed 
in  G-CSF +/-  mice,  where  the  neutrophil  counts  of the 
G-CSF +/-  mice  are  67%  of the  G-CSF +/+  (23).  The  ob- 
served  gene  dosage  effect  suggests  that  mild  congenital 
thrombocytopenias  may be caused by mutation  of a  single 
allele of the TPO gene. 
Interestingly,  the  TPO -/-  animals  are  not  completely 
devoid  of platelets,  which  suggests  that  although  c-mpl/ 
TPO  activation is the key regulator  of megakaryocyte and 
platelet  production,  alternative  mechanisms  may  be  trig- 
gered in the c-mpl  -/-  orTPO  -/-  mice to promote mega- 
karyocytopoiesis.  Histopathology  of  paraffin-embedded 
sternums also demonstrated  a major loss ofmegakaryocytes 
in  the  bone  marrow  of TPO -/:-  mice  (<10%  of control) 
Figure  2.  Platelet  and megakaryocyte analysis in  TPO  -/-  mice.  (A) 
Blood was collected by retroorbital venous puncture  and analyzed in a 
hematology analyzer (System  9000 Dill] Serono-Baker Diagnostics, Allen- 
town, PA) to determine platelet counts, n =  5 mice per group. (B) Ploidy 
analysis of bone marrow megakaryocytes.  A Percoll step gradient (20, 40, 
60, and 80%) was used to enrich for megakaryocytes in bone marrow. 
Cells from the 20/40% interface were stained with anti-CD61  (integrin- 
~3 chain)-FITC and the DNA intercalating fluorescent dye propidium io- 
dide. The DNA content  in CD61  +  cells was quantified by two-color 
flow cytometry. 
and  heterozygous  mice  (60%  of control).  Ploidy  of bone 
marrow megakaryocytes was measured  to identify  qualita- 
tive differences between the megakaryocytes present in the 
TPO -/-  compared  with  normal  mice  (Fig.  2  B).  These 
data  indicate  a  10-fold  drop  in  the  32N  megakaryocytes 
and a  5-fold drop in the  16N  megakaryocytes.  Thus  there 
is  a  reduction  not  only in  the  absolute  number  of mega- 
karyocytes but  also  in  their  maturity  as measured  by their 
DNA content.  This result demonstrates that TPO  regulates 
the  maturation  of  megakaryocytes  at  the  physiological 
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Figure 3.  Effect  of TPO, SCF, and IL-3 alone or in combinations on 
CFU-Meg colonies. Megakaryocyte colony formation  was  assayed in 
semisolid  agar culture of bone marrow of 6-10-wk-old mice as described 
(8) in the presence of 100 ng/ml of the various cytokines. After 7 d, the 
plates were dried and stained for acetylcholinesterase  (18). Megakaryocyte 
colonies were defined as stained colonies containing three or more cells. 
level. There was no significant difference in red blood cells, 
total white blood cells, neutrophils, bands, and eosinophils 
in peripheral blood between TPO +/+  and TPO -/-  mice, 
as determined by differentia/cell counts.  The size and cel- 
lularity of lymphoid organs were also unaffected. Thus, dis- 
ruption of the TPO  gene results in a highly specific loss of 
both  megakaryocytes and  ptatelets, leaving other  cell lin- 
eages unaffected. 
To determine whether TPO affects an early or late stage 
of megakaryocyte development, we tested the physiologi- 
cal  influence  of TPO  on  the  number  of bone  marrow 
megakaryocyte progenitor cells by establishing CFU-meg 
cultures from  TPO +/+  and TPO -/-  mice  in  serum  con- 
taining semisolid media in the presence of TPO,  stem cell 
factor (SCF), and IL-3 (Fig. 3). Analysis of the number of 
CFU-meg colonies after acetylcholinesterase staining indi- 
cates that rnurine TPO  supports the growth of CFU-megs 
alone, synergizes with SCF, and is additive with IL-3 as de- 
scribed (11).  However, the number  of colonies present in 
the cultures from TPO -/-  cells were greatly reduced corn- 
pared with  the  wild type  (mTPO,  10  -  3  vs.  2  +  0.5; 
mTPO  +  SCF, 38  +  5 vs. 5  +  4). This effect was also ob- 
served in CFU-meg cultures stimulated by IL-3 (34  -+  10 
vs. 8  +  6), indicating that IL-3 does not stimulate a popula- 
tion of progenitor cells independent of TPO.  The involve- 
ment of TPO  and c-mpl at an early stage of megakaryocy- 
topoiesis  as  indicated  by  the  reduction  in  CFU-meg 
progenitors present in the bone marrow of TPO -/-  mice is 
consistent with the detection of c-mpl expression in AA4  + 
Sca  + murine stem cell population (12). 
To determine whether it is possible to rescue the mutant 
phenotype,  platelet production  in  response  to  TPO  was 
compared  in  c-mpl  -/-  or  TPO -/-  and  wild-type mice. 
The  TPO  effect  is  completely missing  in  the  c-mpl  -/- 
mice, confirming that this receptor has been properly dis- 
rupted on a functional level and that other receptors do not 
exist that respond to TPO  (data not shown). The TPO -/ 
and TPO -/+ mice do respond to TPO  in a similar fashion 
to  wild-type mice,  giving  a  fivefold increase  in  platelets 
(Fig. 4).  It takes 12 d  of TPO  treatment for TPO -/-  mice 
to reach normal levels, which is probably due to the lower 
initial  starting  population  of megakaryocyte  progenitors. 
The platelet levels in TPO -/-  mice eventually surpass un- 
treated wild-type levels (Fig. 4), indicating that the protein 
replacement therapy using TPO can correct the engineered 
genetic defect. 
These  results,  combined  with  those  observed  in  the 
c-mpl  -/-  mice, demonstrate that there is no redundancy in 
the TPO/mpl  system where a single ligand mediates its ef- 
fect through a unique receptor. The thrombocytopenia ob- 
served in the TPO -/- mice indicates that TPO is the major 
physiological regulator of megakaryocytopoiesis. The phe- 
notype  of the  TPO -/-  mice  provides  direct evidence  of 
the  dual function  of thrombopoietin  at  the  physiological 
level. TPO  can act both  as an  early acting factor and  as a 
late  maturation  factor,  as  indicated  by  ploidy analysis  of 
bone  marrow  megakaryocytes and  CFU-meg assays.  Fur- 
thermore,  the 80-90%  reduction in megakaryocyte num- 
bers in the TPO -/-  and the 40% reduction in the TPO +/- 
mice lead to a proportional reduction in the number of cir- 
culating platelets.  These  results  suggest  that  TPO  is  pre- 
dominantly involved in  megakaryocytopoiesis and  not  in 
Control 
10- 
5- 
o- 
0  TPO +/+  ] 
TPO +/- 1  0 TPO-/- 
A  ~  IIh  ~  ilk 
0  7  12  14  19  21 
Days 
i  I  i  i  i 
0  7  12  14  19  21 
o  10- 
E 
g 
O 
O 
13. 
0 
Figure  4.  TPO -/-, TPO +/-, or wild-type mice were 
injected subcutaneously with  either PBS  or  1 Ixg TPO 
twice daily for 14 d. Blood samples  were taken by retroor- 
bital venous puncture on days 0, 7, 12, 14, 19, and 21 and 
were analyzed in a hematology analyzer, n =  6 mice per 
group. Data are indicated as platelet number. 
654  Megakaryocytopoiesis  in Thrombopoietin-deficient Mice the  latter  stages  of platelet  formation.  Treatment  of wild- 
type mice with pharmacological doses of TPO causes a 20- 
fold increase  in megakaryocytes but only a 5-fold increase 
in platelets  (7,  9), suggesting that other mechanisms or fac- 
tor(s)  may be required for platelet  formation and are now 
limiting  even  in  the  presence  of elevated  TPO.  Targeted 
disruption  of the p45  NF-E2 gene  (24)  also indicates  that 
TPO  may not be required  for the terminal  differentiation 
ofmegakaryocytes and platelet formation. These mice have 
a fully functional TPO/mpl system and have normal mega- 
karyocyte levels.  However, these megakaryocytes show no 
cytoplasmic platelet formation. Availability of these models 
constitutes a powerful tool to dissect the molecular mecha- 
nisms of megakaryocytopoiesis and platelet formation. 
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